In vivo interferon system assessed by 2′-5′ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin

Hepatology Research

Volumn 38, Issue 12, 2008, Pages 1213-1220

  Shindo, Michiko ^a   Hamada, Kazushige ^b   Morikawa, Teruhisa ^a   Harano, Yuichi ^a   Nakajima, Tomoaki ^a   Okuno, Tadao ^a  

^a Akashi Municipal Hospital   (Japan)

^b KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

2 5AS; Chronic HCV; Peginterferon

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; GENE INDUCTION; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 55449109592     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00397.x     Document Type: Article

References (15)

1. Alter Mj, Kruszon-Moran D, Naiman O et al. The prevalence of HCV virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
2. Bartenschlager R, Frese M, Pietschmann T. Novel insights into HCV virus replication and persistence. Adv Virus Res 2004; 63: 71-80.
3. Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for intial treatment of chronic HCV: A randomized trial. Lancet 2001; 358: 958-65.
4. Fried MW, Shiffman ML, Reddy KR et al. Combination of peginterferon alfa 2a (40kD) plus ribavirin in patients with chronic HCV infection. N Engl J Med 2002; 347: 975-82.
5. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon alfa 2a and ribavirin combination therapy in chronic HCV: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
6. Ferenci P, Fried MW, Schiffman ML et al. Predicting sustained virological responses in chronic HCV pateitns treated with peginterferon alfa 2a (40kD)/ribavirin. J Hepatol 2005; 43: 453-71.
7. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24weeks peginterferon alpha 2a (40 kD)/ ribavirin therapy. Hepatology 2005; 43: 954-60.
8. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa 2b plus ribavirin in patients with chronic HCV. Hepatology 2003; 38: 645-52.
9. Kerr IM, Brown RE. PppA2′p5′A2′p5′A: An inhibitor of protein systhesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci USA 1978; 75: 256-60.
10. Schattner A, Mercelin G, Wallach D et al. Monitoring of interferon treatment by assay of 2′-5′ oligoadenylate synthetase in human peripheral white blood cells. J Interferon Res 1981; 1: 587-94.
11. Sawai H, Ishibashi K, Itoh M et al. Sensitive radioimmunoassay for 2′-5′ oligoadenylates using a novel 125I-labeled derivative of 2′-5′-triadenylate 5′-triphosphate. J Biochem 1985; 98: 999-1005.
12. Sugino H, Mitani I, Koike M et al. Detection of elevated 2′-5′ oligoadenylate synthetase in serum from children with various infectious diseases. J Clin Microvirol 1986; 24: 478-81.
13. Shindo M, Okuno T, Matsumoto M et al. Serum 2′-5′ oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B. Hepatology 1988; 8: 366-78.
14. Di Bisceglie AM, Fan X, Chambers T, Strinko J. Pharmacokinetics, pharmacodynamics and HCV viral kinetics during antiviral therapy: The null responder. J Med Virol 2006; 78: 446-51.
15. Roberts S, Weltman M, Crawford D et al. Rapid and early virological response rates are increased with 12week 360 (g/week peginterferon alfa 2a and standard ribavirin in HCV genotype 1 treatment naïve patients: Efficacy and safety analysis of the induction phase of the CHARIOT study. Hepatology 2007; 46: 257A.